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Background: Systemic thrombolysis with recombinant tissue plasminogen activator (rt-PA) is the standard of acute
stroke care. Its potential to increase the risk of secondary intracerebral hemorrhage, especially if administered late,
has been ascribed to its proteolytic activity that has detrimental effects on blood–brain barrier (BBB) integrity after
stroke. FTY720 has been shown to protect endothelial barriers in several disease models such as endotoxin-induced
pulmonary edema and therefore is a promising candidate to counteract the deleterious effects of rt-PA. Besides
that, every putative neuroprotectant that will be eventually forwarded into clinical trials should be tested in
conjunction with rt-PA.
Methods: We subjected C57Bl/6 mice to 3 h filament-induced tMCAO and postoperatively randomized them into four
groups (n = 18/group) who received the following treatments directly prior to reperfusion: 1) vehicle-treatment, 2)
FTY720 1 mg/kg i.p., 3) rt-PA 10 mg/kg i.v. or 4) FTY720 and rt-PA as a combination therapy. We measured functional
neurological outcome, BBB disruption by quantification of EB extravasation and MMP-9 activity by gelatin zymography.
Results: We observed a noticeable increase in mortality in the rt-PA/FTY720 cotreatment group (61%) as
compared to the vehicle (33%), the FTY720 (39%) and the rt-PA group (44%). Overall, functional neurological
outcome did not differ significantly between groups and FTY720 had no effect on rt-PA- and stroke-induced BBB
disruption and MMP-9 activation.
Conclusions: Our data show that FTY720 does not improve functional outcome and BBB integrity in large
hemispheric infarctions, neither alone nor in conjunction with rt-PA. These findings stand in contrast to a recently
published study that showed beneficial effects of FTY720 in combination with thrombolysis in a thrombotic model
of MCAO leading to circumscript cortical infarctions. They might therefore represent a caveat that the
coadministration of these two drugs might lead to excess mortality in the setting of a severe stroke.
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Thrombolysis with recombinant human tissue plasminogen
activator (rt-PA) is the only approved and evidence-based
medical therapy for ischemic stroke. Within the narrow
therapeutic time window of 4.5 h, it confers a clear net
benefit to all stroke patients who receive thrombolysis
which comes at the cost of an increased risk of secondary
intracerebral hemorrhage for the individual patient, mostly
caused by hemorrhagic transformation (HT) of the in-
farcted brain tissue [1].
Magnetic resonance imaging studies in acute stroke pa-
tients have shown that blood–brain barrier (BBB) disrup-
tion is significantly more prevalent in stroke patients who
received thrombolysis than in untreated stroke patients [2].
Based on the description of HARM (hyperintense acute re-
perfusion marker) which was defined as the presence of
gadolinium extravasation into the cerebrospinal fluid (CSF)
space adjacent to the infarction on the fluid-attenuated in-
version recovery (FLAIR) sequence of a follow up scan
after gadolinium injection for a scan that took place a few
hours earlier, it became evident that preceeding BBB dis-
ruption was present in 73% of patients who developed
hemorrhagic transformation within the next hours [3].
These observations were supported by animal studies
showing that cerebral ischemia leads to an increase of
matrix-metalloproteinase (MMP) activity, especially of
MMP-9 which follows the same time course as BBB dis-
ruption after experimental stroke and that both are aggra-
vated by treatment with rt-PA [4] and correlate with HT
[5]. Therefore, combination therapies with drugs that pro-
tect endothelial barrier function seem to be a reasonable
approach to limit the risks of rt-PA treatment.
One of these substances is the sphingosine 1-phosphate
analog FTY720, an immunomodulator that has been mar-
keted in 2010 for the treatment of relapsing-remitting mul-
tiple sclerosis (MS). The presumed mechanism of this drug
is the induction of peripheral lymphocytopenia that is
caused by agonist-induced internalization of the S1P1 re-
ceptor of B and T lymphocytes which limits lymphocyte
egress from primary lymphoid organs [6]. But beside its
effects on immune cell trafficking, FTY720 also has effects
on neurons, glia, and progenitor cells in the brain and
an effect on the BBB can be presumed [7]. Interestingly,
FTY720 treatment led to a downregulation of inflammatory
genes including MMP-9 and to an increased expression of
its counterpart tissue inhibitor of metalloproteinase (TIMP)
in experimental autoimmune encephalitis (EAE) [8]. Given
as a rescue therapy, FTY720 reduced BBB leakiness after
disease onset [8]. Studies in other vascular beds have shown
that FTY720 can protect endothelial cells from apoptotic
cell death [9]. However, there are conflicting data on the
net effect of S1P receptor agonism on endothelial barrier
function, with FTY720 being protective in a model of pul-
monary edema caused by systemic LPS injection [10] whileit has deleterious effects in a model of bleomycin-induced
pulmonary fibrosis [11].
A neuroprotective effect of FTY720 in the acute phase
of stroke has been shown in several experimental studies
[12-14]. From a translational point of view, every neuro-
protectant that is aimed at ameliorating acute brain dam-
age in the first hours within stroke onset should be tested
in conjunction with rt-PA. Therefore, the aim of this study
was to assess the effect of FTY720 in conjunction with rt-
PA treatment in an experimental model of stroke and its
effect of stroke- and rt-PA-induced BBB disruption and
matrix metalloproteinase expression.
Methods
Experimental model of middle cerebral artery occlusion
C57Bl/6 mice (Charles River Laboratories, Sulzfeld, Germany)
were used at 10–12 weeks of age. All experiments
were approved by the local governmental authorities
(Regierungspräsidium Darmstadt, Germany, approval
number F143/51) and conducted in accordance with
the National Institutes of Health Guide for the Care
and Use of Laboratory Animals. Mice were subjected
to transient middle cerebral artery occlusion (MCAO)
as described previously [15]. Briefly, mice were anesthe-
tized with 1.5–2.5% isoflurane (Forene; Abbott,
Wiesbaden, Germany) and 0.1 mg/kg buprenorphine
(Temgesic®; Essex Pharma, Munich, Germany) under
spontaneous respiration. Focal cerebral ischemia was
induced by inserting a custom made filament with a tip
diameter of 0.23 mm (Doccol, Sharon, USA) into the
middle cerebral artery (MCA). Regional cerebral blood
flow was monitored by laser Doppler flowmetry (PF5010,
Perimed; Stockholm, Sweden) to confirm vessel occlusion.
After an occlusion time of 3 h, the filament was withdrawn
to initiate reperfusion. After the operation, mice were
allowed to recover from anesthesia with free access to food
and water. At the end of a 24 h observation period, mice
were lethally anaesthetized and perfused transcardially with
PBS. Brains were removed quickly and divided into ische-
mic and non-ischemic hemispheres before they were fro-
zen and stored at −80°C to await further procedures.
Brains from mice that had died within the 24 h observation
period were harvested without prior transcardial perfusion.
Sample size calculation, experimental groups and
substance application
We based our sample size calculation on the quantifi-
able parameters Evans Blue extravasation and matrix
metalloproteinase-9 activatity. Assuming an increase of
25% in these two parameters between the ischemic
hemispheres of the vehicle-treated and rt-PA-treated mice
that has been shown in previous studies and a standard
deviation of 33% of the respective mean values (Cohen’s D
0.85), a group size of 18 animals was necessary to show
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error of < 0.5 [16]. After the MCAO operation and prior
to reperfusion, we randomized 18 mice per group into the
four treatment groups: 1) vehicle-treatment, 2) 1 FTY720
1 mg/kg 3) rt-PA 10 mg/kg, or 4) FTY720 and rt-PA as a
combination therapy. The mice received either FTY720
(1 mg/kg, dissolved in 0,9% NaCl; Fingolimod; Cayman
Chemicals, Ann Arbor, USA) or saline i.p. in combination
with an i.v. bolus of either rt-PA (10 mg/kg; Actilyse®;
Boehringer Ingelheim, Ingelheim, Germany) or aqua ad
injectabilia. The operator was blinded to the pharmaceut-
ical treatment during the whole study. Additionally, we
assessed whether preconditioning of the rt-PA-solution by
exposure to a fibrin-containing clot would enhance its
deleterious effects on the blood–brain barrier. To this end,
blood was drawn from a donor mouse to generate a
spontaneously-formed blood clot. Rt-PA was incubated
with this blood clot for 30 min under gentle shaking, gen-
erating “activated” rt-PA (Art-PA). We performed 3 h of
MCAO in two sets of mice that received an i.v. bolus of ei-
ther rt-PA (10 mg/kg) or Art-PA (10 mg/kg).
FACS analysis of lymphocyte counts
500 μl of blood were drawn into EDTA-coated tubes from
3 animals per group (1 mg/kg FTY720 vs. saline) 2 h after
the injection of FTY720 or vehicle, cells were spun down
and erythrocytes were lysed with red cell lysis buffer (8,3 g
NH4Cl in 0,01 mol/L Tris–HCl, pH 7,4). After washing
with RPMI, samples were incubated with FACS buffer (1%
FCS in PBS/0,01% NaN3) and the respective antibodies
(Rat anti-mouse CD4 [APC-coupled, Southern Biotech,
1540–11], rat anti-mouse CD8 [PerCP-CTM5.5-coupled,
BD Pharmingen, 551162]) for 30 minutes before overnight
fixation in 4% PFA in PBS at 4°C. Samples were analyzed
on a FACSCalibur with the CellQuestPro Software (BD
Biosciences).
Evaluation of neurological function
Neurological function was evaluated at 3 h directly
prior to reperfusion and at 24 h post-MCAO on a 14
point scale modified from Chen et al. [17] testing
hemiparesis, gait, coordination and sensory functions
(Additional file 1: Table S1).
Determination of blood–brain barrier leakage
To assess blood–brain barrier leakage, the extravasation
of the autofluorescent dye Evans Blue (EB) that binds to
plasma albumin was quantified from brain hemispheres
as described before [5]. 23 h after MCAO, 200 μl of 2%
Evans Blue in 0.9% NaCl were injected into the retro-
bulbar venous plexus and allowed to circulate for 1 h
prior to transcardial perfusion and brain removal.
Brain samples were homogenized in lysis buffer as
described above and additionally with ultrasound.Protein precipitation was obtained by adding 50%
trichloroacetic acid. The supernatant was diluted 4fold
with ethanol. The amount of Evans blue dye was mea-
sured by a microplate fluorescence reader (excitation
600 nm, emission 650 nm; SpectraMax M5; Molecular
Devices, Sunnyvale, USA).MMP-9 activity
Gelatin zymography was used to measure the levels of
MMP-9 activity in the brain samples as described previ-
ously [5,18]. We analyzed the brains of all mice, includ-
ing those that did not survive the observation period.
Brain hemispheres were homogenized in ice-cold lysis
buffer contanining protease inhibitors. After centrifuga-
tion, the supernatant was collected and total protein
concentration of each sample was determined by the
Bradford assay (Nanoquant, Roth, Karlsruhe, Germany).
Equal volumes of total protein extracts in sample buffer
(4% SDS, 0.005% bromphenol blue, and 20% glycerol)
were loaded onto 10% polyacrylamide gels containing
0.1% gelatin as a substrate. After electrophoresis, the
gels were incubated in 2.5% Triton X-100 at room
temperature for 30 min with gentle agitation and
stained with 0.5% Coomassie Blue G250. For densitom-
etry, gels were scanned, inverted and integrated density
of the bands was quantified with NIH image J 1.44p.MMP-9 protein expression
We evaluated MMP-9 expression on the protein level
by Western Blotting. Samples of equal total protein con-
tent were loaded onto polyacrylamide gels. After migra-
tion, proteins were electrotransferred onto a nitrocellulose
blotting membrane. To confirm successful transfer, the
membrane was stained with Ponceau S. It was then
blocked in 5% dry milk and 0.05% Tween-20 for 1 h at
room temperature under gentle agitation. After extensive
washing, the membrane was incubated with the primary
antibody (Anti-MMP-9 rabbit polyclonal; Millipore,
Billerica, USA) over night. After exposition to a second
antibody (goat anti-rabbit antibody; Bio-Rad, Munich,
Germany), the blots were developed with a chemilu-
minescence reagent on hyperfilm.Statistical analysis
Graph Pad Prism 4 (Graph Pad Software Inc., La Jolla,
CA, USA) was used for statistical analysis. Results are
expressed as means +/− standard deviation. Statistical sig-
nificance of the differences between groups was evaluated
with One-way ANOVA with Bonferroni’s correction for
parametric values or the Kruskal-Wallis test with Dunn’s
correction for nonparametric values.
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Intraperitoneal injection of FTY720 leads to a rapid
decrease of blood lymphocyte counts in mice
To verify efficient uptake and potency of FTY720 via
the route of administration that we chose for our ex-
periment, we sampled blood 2 h after i.p. injection of
1 mg/kg FTY720. Fluorescence-activated cell sorting
(FACS) analysis of CD4+ and CD8+ T cell populations
showed a significant decrease in circulating T lympho-
cytes to 22.5% for CD8+ T cells and 4.3% for CD4+ T
cells as compared to vehicle treated mice (Figure 1).
FTY720 in conjunction with rt-PA does not improve
survival or functional neurological outcome in large
hemispheric infarctions
Mice were randomized into four groups (n = 18/group) to
receive either 10 mg/kg rt-PA or vehicle i.v. at the end of
the 3 h MCAO period in combination with either 1 mg/kg
FTY720 or vehicle i.p. The vehicle only-treated group
showed a mortality of 33%. Interestingly, the group who
received FTY720 in conjunction with rt-PA showed a con-
siderably higher mortality of 61% (Figure 2A). There were
no significant differences between groups in the functionalFigure 1 FTY720 leads to a rapid decrease of blood
lymphocyte counts. We sampled blood 2 h after i.p. injection of
FTY720 (1 mg/kg). FACS analysis showed a significant reduction of
both CD4+ and to a lesser extent CD8+ T cells (n = 3/group).
Statistical significance between groups was tested with two-tailed
Student’s t-test for unpaired values. * p < 0.05.neurological examination with the 14-point neuroscore
mNSS (Figure 2B).
FTY720 does not enhance blood–brain barrier integrity
in large hemispheric infarcts alone or in combination
with rt-PA
Brain weight of the ischemic hemisphere was increased by
30–40% in comparison to the non-ischemic hemisphere.
Neither rt-PA nor FTY720 treatment alone had an influ-
ence on this very crude measure of brain swelling and also
rt-PA in combination with FTY720 did not lead to signifi-
cant changes in wet brain weight. We only included mice
whose ischemic hemisphere showed at least a weight in-
crease by 10% to exclude all mice who showed postmortal
global brain swelling (Figure 3A) after being found dead
during the observation period. All mice who survived the
24 h observation period received 200 μl 2% Evans Blue
(EB) i.v. one h prior to sacrifice to assess BBB permeability
for macromolecules such as albumin. Fluorometric EBFigure 2 FTY720 in conjunction with rt-PA does not improve
survival or functional neurological outcome in large
hemispheric infarctions. A) Mice were randomized to four
different treatment groups (n = 18/group). Operation, treatment and
neurological evaluation were performed in a blinded fashion. The
mortality rate of each treatment group is given over the respective
column. B) Functional neurological outcome on a 14-point scoring
scale was evaluated at 24 h after the onset of ischemia. Each dot
represents an individual mouse. Bars depict median values. Statistical
significance of the differences between groups was tested with
Kruskal Wallis test with Dunn’s correction for multiple comparisons.
ns indicates not significant.
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perfused mice did also not show an alteration of stroke-
induced EB extravasation by rt-PA, FTY720 or the com-
bination of both substances (Figure 3B).
Neither rt-PA nor FTY720 induce significant changes in
MMP-9 activity in brain homogenates 24 h after MCAO
Matrix metalloproteinase-9 (MMP-9) is a serine protease
that becomes activated in case of ischemic brain injury and
has been shown to be a key mediator of blood–brain bar-
rier breakdown in experimental stroke [5]. We performedFigure 3 FTY720 does not enhance blood–brain barrier patency
in large hemispheric infarcts neither alone nor in combination
with rt-PA. A) For the determination of wet brain weight, the
cerebellum was discarded and brain hemispheres were frozen
separately at −80°C. The frozen brain hemispheres were weighed
prior to homogenization. Only mice whose ischemic hemisphere (I)
showed an increase of wet brain weight of≥ 10% in comparison to
the non-ischemic hemisphere (NI) were included in our analysis. B)
EB (200 μl of a 2% solution) was injected 1 h prior to sacrifice and
transcardial perfusion. We excluded mice who showed more EB
extravasation into the NI hemisphere and mice who died within the
EB circulation time of 1 h. Statistical significance of the differences
between groups was tested with One-way ANOVA with Bonferroni
correction. ns indicates not significant.gelatin zymography to assess MMP-9 activity in the in-
farcted and non-infarcted hemisphere. While there was a
clear, approximately five-fold increase in the infarcted
hemisphere, much to our surprise, the administration of
FTY720 or rt-PA or the combination of both substances at
the end of the 3 h MCAO period did not lead to significant
changes in MMP-9 activity (Figure 4A). We performed ex-
emplary Western Blots of MMP-9 and found that MMP-9
activity as assessed by gelatin zymography was highly cor-
related with MMP-9 protein expression (Figure 4B).
Activated rt-PA (Art-PA) does not lead to a further increase
in blood–brain barrier breakdown after cerebral ischemia
We aimed to clarify the lack of a clear detrimental effect of
rt-PA on BBB integrity and MMP-9 activity in our experi-
mental setting. Since it is conceivable that rt-PA only de-
velops its proteolytic effect when it is activated by a fibrin
rich clot of adequate surface, we preincubated rt-PA with a
spontaneously-formed autologous blood clot for 30 min at
room temperature prior to injection after MCAO to gen-
erate activated rt-PA (Art-PA). This preconditioning of rt-
PA, however, also did not lead to the 2–4fold increase of
the cerebral ischemia-induced MMP-9 activity in the is-
chemic hemisphere that has been reported elsewhere for
the filament occlusion model [4] (Figure 5).
Discussion
We found no relevant protective effect of FTY720 when
applied in conjunction with rt-PA in an experimental
model of large hemispheric strokes, neither on functional
neurological outcome nor on markers of BBB disruption.
In contrast, our data rather point towards safety concerns
against the coadministration of these two drugs in patients
with severe strokes.
Analyzing mortality, we found a noticeable difference
between the vehicle group (33%) and the groups with ad-
ministration of FTY720 alone (39%) or rt-PA alone (44%)
on the one hand and the cotreatment group who received
rt-PA in conjunction with FTY720 (61%) on the other
hand. When evaluating functional outcome after 24 h on
the 14 point neuroscore including dead animals which
were assigned the maximal score of 14, the differences be-
tween groups were not statistically significant.
These data are in some aspects remindful of the results
of the multicentric clinical phase II/III trial of eryhtrom-
poietin (EPO) published in 2009, which assessed its safety
and efficacy in acute stroke [19]. This clinical trial was pre-
ceded by promising experimental studies that had shown
a robust neuroprotective effects and a clinical phase I trial
of EPO as a monotherapy in the acute phase of stroke [20]
that had demonstrated adequate safety. In contrast, the
phase II/III trial, which for the first time allowed systemic
thrombolysis in conjunction with EPO treatment, failed to
show efficacy. Characteristics of this trial population were
Figure 4 Neither rt-PA nor FTY720 induce significant changes in MMP-9 activity in brain homogenates 24 h after MCAO. A) Non-ischemic (NI)
and ischemic (I) hemispheres were homogenized separately in ice-cold cell lysis buffer containing protease inhibitors and subjected to acrylamide gel
electrophoresis on a gel containing 0.1% gelatin. Photographs of the Coomassie blue-stained gels were inverted and the MMP-9 band at 84 kDa
densitometrically evaluated. We excluded all mice who showed greater MMP-9 activity in the NI as compared to the I hemisphere. B) We compared
MMP-9 expression on the protein level (Western Blot, upper panel) with MMP-9 gelatinase activity (zymography, middle panel) from identical samples of
brain tissue. Total protein staining with the azo dye Ponceau S served as a loading control.
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tration of systemic thrombolysis in 60% of patients [19].
There was an excess of mortality in the group of
erythropoietin-treated patients compared to the placebo
group and the patients who received erythropoietin as a
cotreatment together with thrombolysis fared distinctly
worse [19]. Therefore, we interpret our data as a caveat that
FTY720, which has shown a beneficial effect on outcome
and infarct size in several different stroke models, might
not be effective if used as a treatment for severe strokes, es-
pecially in conjunction with systemic thrombolysis.
Regrettably, our data do not allow a functional explan-
ation of the excess mortality of rt-PA treatment in conjunc-
tion with FTY720. Focusing on BBB analyses, we did
not perform a quantification of hemorrhagic transform-
ation, e.g. with brain imaging or a hemoglobin assay.
Therefore, we have no information on whether the com-
bination therapy led to an increase in hemorrhagic trans-
formation. Concerning alternative extracranial causes ofmortality, FTY720 has been shown to induce bradycardia
[21], bronchoconstriction and mild pulmonary edema [22]
in mice and humans. Besides that, the paucity of circulat-
ing lymphocytes could in principle entrain an increased
susceptibility towards infections, even though we showed
previously, that FTY720 does not increase the rate of
stroke associated pneumonia in mice [23] and similar find-
ings have been shown for equally specific immunomodula-
tory interventions in experimental stroke [24]. However,
these symptoms are no common side effects of rt-PA
treatment and should have occurred to the same extent in
the group receiving FTY720 alone if they were to explain
this excess mortality.
Much to our surprise, we did not detect a deleterious ef-
fect of rt-PA alone on stroke induced BBB dysfunction.
This is at odds with many experimental studies describing
an aggravating effect of rt-PA on BBB disruption after
stroke [4,5]. One possible explanation could have been that
rt-PA was not biologically active in our experimental
Figure 5 Activated rt-PA (Art-PA) does not lead to a further
increase in blood–brain barrier breakdown after cerebral ischemia.
Rt-PA (1 mg/ml) was either injected directly in the dose of 10 mg/kg in 2
mice after MCAO (first four lanes, homogenates of the non-ischemic and
ischemic hemisphere of each mouse) or incubated with a
spontaneously-generated blood clot for 30 minutes under gentle shaking
prior to injection in 2 mice (last four lanes). MMP-9 activity was assessed
with gelatinase zymography. Bands were analyzed densitometrically.
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We cannot directly prove an effect of rt-PA, but previ-
ous studies from our group using the same injection
technique showed clear effects of rt-PA on HT after
stroke [25]. Interestingly, the increase of BBB disruption
after stroke has been shown to be greater in embolic
than in mechanical models of stroke as the filament-
occlusion used in the present study [4]. There are even
reports that the administration of rt-PA in the filament-
model per se does not increase BBB damage unless it is
“activated” by preincubation with a clot [26,27]. How-
ever, in our hands, even after preincubation of the rt-PA
solution with an autologous blood clot, we did not find
a relevant increase in the ischemia-induced MMP-9 ac-
tivity by activated rt-PA. Therefore, use of preactivated
rt-PA did not serve to improve our experimental model.
Against the backdrop of our own observations and the
published studies on FTY720 in experimental stroke
studies, it is somewhat surprising that we did not find a
beneficial effect of FTY720 on functional outcome in
this experiment. We ascribe this discrepancy to the long
MCAO occlusion time which we chose to induce max-
imal brain damage in order to sensitively detect HT after
rt-PA treatment. We did not measure ischemic lesion
size in this study. It is conceivable that while ischemic
lesion size was reduced by FTY720, this did not translate
into clinical benefit anymore because of the severity
of the ischemic insult, explained by a ceiling effect of
the functional neuroscore. We ascertained the timelybiological efficacy of FTY720 in the chosen mode of ap-
plication by a quantification of blood lymphocytopenia
via FACS analysis, shown in the first figure.
Recently, Campos et al. reported on a beneficial effect
of FTY720 in thrombolysis which was only manifest
when rt-PA was applied late, i.e. 180 min after vessel oc-
clusion as opposed to 30 min [28]. They made use of
distal MCAO by direct thrombin injection that led to
circumscript cortical infarctions with reperfusion upon
rt-PA treatment. FTY720 alone led to a reduction of le-
sion size but also the combination therapy of FTY720
and rt-PA applied at 180 min reduced lesion size in
comparison to vehicle treatment. Interestingly, they were
able to demonstrate that FTY720 reduces rt-PA induced
EB extravasation after stroke and rt-PA as a marker for
BBB dysfunction, even after normalization for the reduc-
tion of lesion size. The main discrepancy between our
studies is the size of the infarction produced by the re-
spective experimental model which might have led to a
ceiling effect in our case, where a modest protective ef-
fect is no longer discernible. We chose large hemispheric
infarctions to induce severe BBB damage in order to in-
crease the aggravation of BBB injury by rt-PA.
From a translational point of view, our data point to-
wards the issue that the protective effect of FTY720 in
acute stroke may be lost in large hemispheric infarctions.
They represent a caveat that the combination therapy of
FTY720 and rt-PA might lead to an excess mortality.Additional file
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